
|Articles|August 29, 2017
Importance of identifying the early emergence of metastatic disease in prostate cancer
In this Urology Times educational supplement, we review the importance of understanding the CRPC–mCRPC transition in order to optimize standard screening procedures and identify patients with early metastatic disease who may benefit from therapeutic intervention.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











